Figure 4. The analysis of unique low molecular weight drug compounds’ structures, which are presented in the WWAD, DrugBank, ChEMBL, and GtoPdb. A) The number of compounds’ structures in the analyzed DBs; B) the number of unique and common structures between the WWAD and compared DBs; C) the number of unique MNA descriptors for all compounds in the compared DBs. The number of unique organic low molecular weight drug compounds: A) in the 49 analyzed NMRs; B) depending on the number of the NMRs in which these substances are presented.